Facilitated percutaneous coronary intervention (PCI) in patients with acute ST-elevation myocardial infarction: comparison of prehospital tirofiban versus fibrinolysis before direct PCI.

[1]  H. Suryapranata,et al.  Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial. , 2004, European heart journal.

[2]  R. Baglini,et al.  Safety of a high bolus dose of tirofiban in patients undergoing coronary stent placement , 2004, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[3]  Klaus Rasmussen,et al.  A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. , 2003, The New England journal of medicine.

[4]  P. Armstrong,et al.  Efficacy and Safety of Tenecteplase in Combination With the Low-Molecular-Weight Heparin Enoxaparin or Unfractionated Heparin in the Prehospital Setting: The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS Randomized Trial in Acute Myocardial Infarction , 2003, Circulation.

[5]  A. Yeung,et al.  Adjunctive Platelet Glycoprotein IIb/IIIa Receptor Inhibition With Tirofiban Before Primary Angioplasty Improves Angiographic Outcomes: Results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) Pilot Trial , 2003, Circulation.

[6]  E. Falk,et al.  Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. , 2003, European heart journal.

[7]  M. Aschermann,et al.  Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial--PRAGUE-2. , 2003, European heart journal.

[8]  E. Braunwald,et al.  Relationship of the TIMI Myocardial Perfusion Grades, Flow Grades, Frame Count, and Percutaneous Coronary Intervention to Long-Term Outcomes After Thrombolytic Administration in Acute Myocardial Infarction , 2002, Circulation.

[9]  A. Gitt,et al.  Langzeitverlauf bei Patienten mit akutem Myokardinfarkt, die mittels Primär-Dilatation oder Thrombolyse behandelt wurden. Ergebnisse der MITRA-Studie , 2002, Zeitschrift für Kardiologie.

[10]  G. Stone,et al.  Normal Flow (TIMI-3) Before Mechanical Reperfusion Therapy Is an Independent Determinant of Survival in Acute Myocardial Infarction: Analysis From the Primary Angioplasty in Myocardial Infarction Trials , 2001, Circulation.

[11]  M. Morice,et al.  Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. , 2001, The New England journal of medicine.

[12]  P. Armstrong,et al.  Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. , 2001 .

[13]  C M Gibson,et al.  Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. , 2000, JAMA.

[14]  S. Greenhouse,et al.  A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial , 1999 .

[15]  F. Werf.  Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial , 1999, The Lancet.

[16]  R. Giugliano,et al.  TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. , 1998, Circulation.

[17]  B. Brodie,et al.  Importance of time to reperfusion for 30-day and late survival and recovery of left ventricular function after primary angioplasty for acute myocardial infarction. , 1998, Journal of the American College of Cardiology.

[18]  E. Braunwald,et al.  TNK-tissue plasminogen activator compared with front-loaded tissue plasminogen activator in acute myocardial infarction: primary results of the TIMI 10B trial , 1997 .

[19]  E. Braunwald,et al.  TIMI frame count: a quantitative method of assessing coronary artery flow. , 1996, Circulation.

[20]  K. Mann,et al.  Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. , 1991, Annals of internal medicine.